Determination of Walking, Balance, Fall Risk and Kinesiophobia in Individulas With Alzheimer's Dementation

Sponsor
Kırıkkale University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05201768
Collaborator
(none)
36
4

Study Details

Study Description

Brief Summary

THE OBJECTIVE OF THE RESEARCHERS IS TO DETERMINE WALKING, BALANCE, FALL RISK AND KINESIOPHOBIA IN INDIVIDUALS WITH ALZHEIMER'S DEMENTATION.

Condition or Disease Intervention/Treatment Phase
  • Other: balance tests,questionnaire

Detailed Description

The gait, balance, fall risks and kinesiophobia of individuals with Alzheimer's Dementia will be evaluated and compared with healthy individuals.

Study Design

Study Type:
Observational
Anticipated Enrollment :
36 participants
Observational Model:
Other
Time Perspective:
Other
Official Title:
Determination of Walking, Balance, Fall Risk and Kinesiophobia in Individulas With Alzheimer's Dementation
Anticipated Study Start Date :
Mar 1, 2022
Anticipated Primary Completion Date :
Jun 1, 2022
Anticipated Study Completion Date :
Jul 1, 2022

Arms and Interventions

Arm Intervention/Treatment
INDIVIDUALS WITH ALZHEIMER

balance and gait will be evaluated survey questions will be asked

Other: balance tests,questionnaire
Individuals will be tested and recorded.

HEALTHY INDIVIDUALS

balance and gait will be evaluated survey questions will be asked

Other: balance tests,questionnaire
Individuals will be tested and recorded.

Outcome Measures

Primary Outcome Measures

  1. Age [5 month]

    between the ages of 50 and 80

  2. Body Mass Index [5 month]

    BMI was recorded in kg/m^2

Secondary Outcome Measures

  1. The Tinetti Gait and Balance Test (TGBT) [5 month]

    TGBT consists of balance and gait subheadings. For balance, there are 13 items, and 9 items for gait. Items are scored as 0 (abnormal), 1 (adaptive) and 2 (normal) for balance, 0 (abnormal), 1 (normal) for gait. The maximum balance score of the patient is 26 and the maximum gait score is 9. Total score (balance + walking) is 35 points.

  2. Mini Mental State Test [5 month]

    It was used to determine the cognitive state before the training. The Mini-Mental State Test was first published by Folstein et al. It consists of eleven items under 5 main headings: orientation, record memory, attention and calculation, recall and language, and the total score is evaluated over 30 points.

  3. Tampa Scale [5 month]

    17 questions is a scale. The scale is used in work-related activities, injury/re-injury and fear-avoidance contains the parameters.

  4. The Time Up Go Test [5 month]

    The timed "Up & Go" measures, in seconds, the time taken by an individual to stand up from a standard arm chair (approximate seat height of 46 cm), walk a distance of 3 meters, turn, walk back to the chair, and sit down again.

  5. The Gait Speed Measurement Test (GSMT) [5 month]

    For GSMT, individuals were asked to walk at a speed they wanted on a flat surface of 14 m. Signs were placed on the 2nd and 12th meters of the test area to minimize the speed changes between walking start and walking finish, and to make a more objective measurement. The walking time at this 10-meter distance was measured with the stopwatch and the results were recorded in sec and the walking speed was determined.

  6. Fall Risk Self-Assessment Scale [5 month]

    It consists of 13 items assessing the risk of falling in the elderly. The answers are yes (1 point) and no (0 points), and individuals who get 4 points or more from the scoring are classified as having a high risk of falling.

Eligibility Criteria

Criteria

Ages Eligible for Study:
50 Years to 80 Years
Sexes Eligible for Study:
All
Inclusion Criteria:
  • INDEPENDENT walker diagnosed with Alzheimer's Dementia
Exclusion Criteria:
  • Having a disability to do physical activity Those who have had an operation in the last 6 months

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Kırıkkale University

Investigators

  • Study Chair: oğuzhan Doğancı, Kırıkkale University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Oguzhan Dogancı, Physiotherapist, Kırıkkale University
ClinicalTrials.gov Identifier:
NCT05201768
Other Study ID Numbers:
  • kku-oguzhandoganci1
First Posted:
Jan 21, 2022
Last Update Posted:
Feb 9, 2022
Last Verified:
Feb 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 9, 2022